Diabetic metastatic castration resistant prostate cancer patients administered mefformin during docetaxel chemotherapy have improved prostate cancer-specific and overall survival

被引：1
|
作者：
Mayer, Michelle
Klotz, Laurence
Venkateswaran, Vasundara
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1434
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study
    Marco Bandini
    Raisa S. Pompe
    Michele Marchioni
    Emanuele Zaffuto
    Giorgio Gandaglia
    Nicola Fossati
    Luca Cindolo
    Francesco Montorsi
    Alberto Briganti
    Fred Saad
    Pierre I. Karakiewicz
    International Urology and Nephrology, 2018, 50 : 71 - 78
  • [22] Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study
    Bandini, Marco
    Pompe, Raisa S.
    Marchioni, Michele
    Zaffuto, Emanuele
    Gandaglia, Giorgio
    Fossati, Nicola
    Cindolo, Luca
    Montorsi, Francesco
    Briganti, Alberto
    Saad, Fred
    Karakiewicz, Pierre I.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (01) : 71 - 78
  • [23] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
    Oh, William K.
    Miao, Raymond
    Vekeman, Francis
    Sung, Jennifer
    Cheng, Wendy Y.
    Gauthier-Loiselle, Marjolaine
    Dhawan, Ravinder
    Duh, Mei Sheng
    MEDICAL ONCOLOGY, 2017, 34 (09)
  • [24] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
    William K. Oh
    Raymond Miao
    Francis Vekeman
    Jennifer Sung
    Wendy Y. Cheng
    Marjolaine Gauthier-Loiselle
    Ravinder Dhawan
    Mei Sheng Duh
    Medical Oncology, 2017, 34
  • [25] Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients
    Rescigno, P.
    Lorente, D.
    Bianchini, D.
    Kolinsky, M.
    Zafeiriou, Z.
    Ferraldeschi, R.
    Mateo, J.
    Recine, F.
    Jayaram, A.
    Rodrigues, D. Nava
    Riisnaes, R.
    Miranda, S.
    Figueiredo, I.
    Crespo, M.
    Mehra, N.
    Perez-Lopez, R.
    Tunariu, N.
    Reid, A.
    Attard, G.
    De Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S496 - S496
  • [26] INTERMITTENT (RECHALLENGE) CHEMOTHERAPY WITH DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Bracarda, Sergio
    Rossi, Marta
    Hamzaj, Alketa
    De Angelis, Verena
    De Simone, Valeria
    Caserta, Claudia
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2009, 20
  • [27] Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito, Kagenori
    Kimura, Takahiro
    Onuma, Hajime
    Tabata, Ryuji
    Shimomura, Tatsuya
    Miki, Kenta
    Tomita, Masayuki
    Egawa, Shin
    PROSTATE, 2018, 78 (07): : 498 - 505
  • [28] Docetaxel response after 3 cycles as a predictor of survival in patients with metastatic castration resistant prostate cancer
    Pinto, A.
    Casado, G.
    Castelo, B.
    Zamora, P.
    Redondo, A.
    Martinez, B.
    Espinosa, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S704
  • [29] Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?
    Watanabe, Masahito
    Kanao, Kent
    Muramatsu, Hiroyuki
    Morinaga, Shingo
    Kajikawa, Keishi
    Kobayashi, Ikuo
    Nishikawa, Genya
    Kato, Yoshiharu
    Nakamura, Kogenta
    Sumitomo, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
    Hung, Sheng-Chun
    Chang, Li-Wen
    Li, Jian-Ri
    Wang, Shian-Shiang
    Yang, Cheng-Kuang
    Chen, Chuan-Shu
    Lu, Kevin
    Chen, Cheng-Che
    Wang, Shu-Chi
    Lin, Chia-Yen
    Chen-Li Cheng
    Ou, Yen-Chuan
    Chiu, Kun-Yuan
    IN VIVO, 2021, 35 (06): : 3509 - 3519
12345